PSMA特异性TGF-β不敏感CD8+ T细胞对前列腺癌的疗效
研究从转移性去势抵抗性前列腺癌(mCRPC)患者外周血采集CD8+ T细胞,通过逆转录病毒构建表达抗PSMA嵌合受体(PZ1)和显性负性TGF-β II型受体(TβRIIDN),使其对TGF-β不敏感。体外实验显示对PC-3-PSMA细胞特异性裂解率达61.58%,动物实验中显著抑制PC3-PSMA肿瘤生长并诱导凋亡和CD8+ T细胞浸润,提示该策略可能为mCRPC提供新治疗途径。
要点
- 从mCRPC患者扩增的PSMA特异性TGF-β不敏感CD8+ T细胞高表达PZ1和胸苷激酶基因。
- 这些细胞对PC-3-PSMA细胞产生61.58%特异性裂解,且生长不被TGF-β抑制。
- 在RAG-1-/-小鼠中显著抑制PC3-PSMA肿瘤,并见大量肿瘤凋亡和CD8+ T细胞浸润。
核心结论
- PSMA特异性TGF-β不敏感CD8+ T细胞可从mCRPC患者成功扩增,并在体外和体内克服肿瘤微环境免疫抑制、控制PSMA表达性前列腺癌。
研究设计与样本
- 研究采用mCRPC患者白细胞分离采集CD8+ T细胞,在FDA批准的细胞处理工作站培养,用逆转录病毒载体构建表达抗PSMA嵌合免疫球蛋白-T细胞受体ζ基因(PZ1)和显性负性TGF-β II型受体(TβRIIDN)的CAR-T细胞;体外用Cr51释放法检测对PC-3和PC-3-PSMA细胞的杀伤,体内用免疫缺陷RAG-1-/-小鼠模型评估抗肿瘤功能。
主要发现
- 从mCRPC患者扩增的PSMA特异性TGF-β不敏感CD8+ T细胞高表达PZ1和胸苷激酶基因,且生长不被TGF-β抑制。
- 经更昔洛韦处理后这些细胞存活率急剧下降。
- 对PC-3-PSMA细胞的特异性裂解率为61.58%。
- 在RAG-1-/-小鼠中,PSMA特异性TGF-β不敏感CD8+ T细胞显著抑制PC3-PSMA肿瘤,与PC3肿瘤相比差异显著。
- 大量肿瘤凋亡和CD8+ T细胞浸润仅见于PC3-PSMA肿瘤。
关键数值与推荐
- 对PC-3-PSMA细胞的特异性裂解率为61.58%。
- 经更昔洛韦处理后细胞存活率急剧下降(原文未报告具体数值)。
临床怎么用
- 该研究表明PSMA特异性TGF-β不敏感CD8+ T细胞可能为雄激素剥夺治疗失败的mCRPC患者提供一种有前景的新免疫治疗途径。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Current immunotherapy has limited efficacy on metastatic castrate-resistant prostate cancer (mCRPC). We therefore sought to improve the antitumor ability of mCRPC patient-derived CD8+ T-cells by the endowment of specificity to prostate-specific membrane antigen (PSMA) and insensitivity to immunosuppressant molecule transforming growth factor-β (TGF-ß) under the control of herpes simplex virus-1 thymidine kinase. CD8+ T-cells were collected by leukapheresis and cultured in a Food and Drug Administration-approved Cell Processing Work Station. We developed a chimeric antigen receptor retroviral construct using an anti-PSMA chimeric immunoglobulin-T-cell receptor(ζ) gene (PZ1) and dominant negative TGF-ß type II receptor (TßRIIDN), that could induce CD8+ T-cells to be PSMA reactive and insensitive to TGF-ß. Cr51 release assay was performed on PC-3 and PC-3-PSMA. The further antitumor functions of PSMA-specific, TGF-ß insensitive CD8+ T-cells was evaluated using an immunodeficient RAG-1-/- mouse model. We found PSMA-specific, TGF-ß insensitive CD8+ T-cells from mCRPC were expanded with strong expression of PZ1 and thymidine kinase genes, and their growth was not suppressed by TGF-ß. The survival of these cells decreased sharply after treatment with ganciclovir. Treatment of PSMA-specific TGF-ß, insensitive CD8+ T-cells was associated with 61.58% specific lysis on PC-3-PSMA, and significantly suppressed PC3-PSMA tumor compared with the PC3 tumor. A large amount of tumor apoptosis and CD8+ T-cell infiltration were found only in the PC3-PSMA tumor. This study verified that PSMA-specific, TGF-ß insensitive CD8+ T-cells derived from mCRPC patients could be successfully expanded and used to overcome the immunosuppressive effects of the tumor microenvironment to control PSMA-expressing PC in vitro and in vivo. This may provide a promising approach for men with mCRPC who fail androgen deprivation therapy. PATIENT SUMMARY: We investigated the role of a novel chimeric antigen receptor T-immunotherapy based on autologous metastatic castrate-resistant prostate cancer patient-derived prostate-specific membrane antigen (PSMA)-specific, transforming growth factor-ß insensitive CD8+ T-cells on PSMA-positive prostate cancer. We found that this chimeric antigen receptor T-cells could kill PSMA-positive prostate cancer specifically. The results suggest that this novel immunotherapy treatment is a potential new approach for men with metastatic castrate-resistant prostate cancer.
引用
- Zhang Q, Helfand BT, Carneiro BA, et al. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. Eur Urol. 2017. PMID: 29275833. doi:10.1016/j.eururo.2017.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。